PASADENA, Calif.--(BUSINESS WIRE)--
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that it
will present at multiple scientific conferences in May.
Scheduled conference presentations include the following:
TIDES 2014 - Providence, RI, May 12-15
May 12, 2014 - An oral presentation titled, "Using Endosomal
Escape Agents for siRNA Delivery in vivo," will be presented at the
workshop entitled "In vivo Delivery of Therapeutic Oligonucleotides:
Challenges, Considerations and Solutions," by David Lewis, Ph.D., Chief
Scientific Officer
May 14, 2014 - An oral presentation titled, "Next Generation
Dynamic Polyconjugates for siRNA Delivery in vivo," will be
presented by Aaron Almeida, Ph.D., Senior Scientist II
10th International Symposium on Polymer Therapeutics - Valencia,
Spain, May 19-21
May 19, 2014 - An oral presentation titled, "Polymer-Based
Vehicles for siRNA Delivery in vivo," will be presented by David
Rozema, Ph.D., Vice President, Chemistry
ASGCT 17th Annual Meeting - Washington,
DC, May 21-24
May 21, 2014 - An oral presentation titled, "Development of an
siRNA-Based Therapeutic for Chronic HBV Infection Using DPC Technology,"
will be presented by David Lewis, Ph.D., Chief Scientific Officer
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
drug delivery technologies to develop targeted drugs based on the RNA
interference mechanism that efficiently silences disease-causing genes.
Arrowhead technologies also enable partners to create peptide-drug
conjugates that specifically home to cell types of interest while
sparing off-target tissues. Arrowhead's pipeline includes clinical
programs in chronic hepatitis B virus and partner-based programs in
obesity and oncology.